CombiGene AB Statistics
CombiGene AB (COJ0) Stock Statistics & Valuation Metrics
Total Valuation
CombiGene AB has a market cap or net worth of EUR 4.31M. The enterprise value is EUR 38.38M.
- Market Cap
- EUR 4.31M
- Enterprise Value
- EUR 38.38M
Share Statistics
CombiGene AB has 19,801,197 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 19,801,197
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
CombiGene AB’s return on equity (ROE) is -0.22 and return on invested capital (ROIC) is -23.38%.
- Return on Equity (ROE)
- -0.22
- Return on Assets (ROA)
- -0.22
- Return on Invested Capital (ROIC)
- -23.38%
- Return on Capital Employed (ROCE)
- -0.23
- Revenue Per Employee
- 0
- Profits Per Employee
- -12.36M
- Employee Count
- 1
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of CombiGene AB is 40.68. CombiGene AB’s PEG ratio is 0.07.
- PE Ratio
- 40.68
- PS Ratio
- 74.02
- PB Ratio
- 0.86
- Price to FCF
- -18.49
- Price to Operating Cash Flow
- -19.00
- PEG Ratio
- 0.07
Income Statement
In the last 12 months, CombiGene AB had revenue of 0 and earned -12.36M in profits. Earnings per share was -0.62.
- Revenue
- 0
- Gross Profit
- -8.16M
- Operating Income
- -12.98M
- Pretax Income
- -12.36M
- Net Income
- -12.36M
- EBITDA
- -7.19M
- Earnings Per Share (EPS)
- -0.62
Cash Flow
In the last 12 months, operating cash flow was -2.57M and capital expenditures 0, giving a free cash flow of -2.57M billion.
- Operating Cash Flow
- -2.57M
- Free Cash Flow
- -2.57M
- Free Cash Flow per Share
- -0.13
Dividends & Yields
CombiGene AB pays an annual dividend of ―, resulting in a dividend yield of 83.57%
- Dividend Per Share
- ―
- Dividend Yield
- 83.57%
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -5.41%
- Earnings Yield
- 2.46%
Stock Price Statistics
- Beta
- 0.41
- 52-Week Price Change
- 6.37%
- 50-Day Moving Average
- 0.15
- 200-Day Moving Average
- 0.15
- Relative Strength Index (RSI)
- 66.64
- Average Volume (3m)
- ―
Important Dates
CombiGene AB upcoming earnings date is Feb 12, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Aug 21, 2026
- Next Earnings Date
- Feb 12, 2027
- Ex-Dividend Date
- ―
Financial Position
CombiGene AB as a current ratio of 5.37, with Debt / Equity ratio of 0.00%
- Current Ratio
- 5.37
- Quick Ratio
- 5.37
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 0.36
- Interest Coverage Ratio
- -156.34
Taxes
In the past 12 months, CombiGene AB has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
CombiGene AB EV to EBITDA ratio is 16.31, with an EV/FCF ratio of -17.28.
- EV to Sales
- 69.18
- EV to EBITDA
- 16.31
- EV to Free Cash Flow
- -17.28
- EV to Operating Cash Flow
- -17.28
Balance Sheet
CombiGene AB has EUR 6.17M in cash and marketable securities with EUR 0.00 in debt, giving a net cash position of EUR 6.17M billion.
- Cash & Marketable Securities
- EUR 6.17M
- Total Debt
- EUR 0.00
- Net Cash
- EUR 6.17M
- Net Cash Per Share
- EUR 0.31
- Tangible Book Value Per Share
- EUR 2.79
Margins
Gross margin is -333.96%, with operating margin of -2335.98%, and net profit margin of 187.07%.
- Gross Margin
- -333.96%
- Operating Margin
- -2335.98%
- Pretax Margin
- 187.07%
- Net Profit Margin
- 187.07%
- EBITDA Margin
- 424.25%
- EBIT Margin
- -341.74%
